Home > Riviste > Minerva Obstetrics and Gynecology > Fascicoli precedenti > Minerva Ginecologica 2018 February;70(1) > Minerva Ginecologica 2018 February;70(1):27-34



Opzioni di pubblicazione
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Ginecologica 2018 February;70(1):27-34

DOI: 10.23736/S0026-4784.17.04151-X


lingua: Inglese

Menopause and hormone replacement therapy: the 2017 Recommendations of the Italian Menopause Society

Marco GAMBACCIANI 1 , Nicoletta BIGLIA 2, Angelo CAGNACCI 3, Salvatore CARUSO 4, Ettore CICINELLI 5, Vincenzo DE LEO 6, Costantino DI CARLO 7, Manuela FARRIS 8, Alessandro GAMBERA 9, Secondo GUASCHINO 10, Antonio LANZONE 11, Anna M. PAOLETTI 12, Novella RUSSO 13, Franco VICARIOTTO 14, Paola VILLA 11, Annibale VOLPE 15 on behalf of the Italian Menopause Society (SIM) 

1 Department of Obstetrics and Gynecology, Pisa University Hospital, Pisa, Italy; 2 Department of Gynecology, University of Turin, Turin, Italy; 3 Department of Obstetrics Gynecology and Pediatrics, Azienda Sanitaria Universitaria Integrata Udine, Udine, Italy; 4 Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy; 5 Department of Obstetrics and Gynecology, School of Medicine, University of Bari, Bari, Italy, 6 Department of Obstetrics and Gynecology, University of Siena, Santa Maria le Scotte Polyclinic, Siena, Italy; 7 Department of Obstetrics and Gynecology, Magna Græcia University, Catanzaro, Italy; 8 Sapienza University of Rome, Rome, Italy; 9 Department of Gynecological Endocrinology, University of Brescia, Brescia, Italy; 10 Burlo Garofolo Children’s Hospital, Trieste, Italy; 11 Department of Obstetrics and Gynecology and Pediatrics, Sacro Cuore Catholic University, Rome, Italy; 12 Department of Surgery, Obstetrics, and Gynecology, University of Cagliari, Cagliari University Hospital, Cagliari, Italy; 13 Demetra Medical Center, Rome, Italy; 14 Humanitas/S.Pio X Hospital, Milan, Italy; 15 Modena Polyclinic, Modena, Italy


Over the last decade, the risk benefits ratio of hormone replacement therapy (HRT) has been reevaluated mainly in tens of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausal Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society). The aim of these recommendations is to provide a simple and updated reference on postmenopausal HRT. The term HRT typically includes estrogen replacement therapy (ERT) and estrogen-progestogen therapy (EPT). EPT can be sequential, when progestogen is added to ERT for 10-14 days a month, or continuous combined when progestogen is administered continuously every day along with a fixed amount of estrogen, In the everyday language, HRT includes also tibolone and the tissue-selective estrogen complex.

KEY WORDS: Health planning guidelines - Hormone replacement therapy - Menopause

inizio pagina